Edgewise Therapeutics, Inc. (EWTX) — 10-Q Filings

10-Q Filings (7)

• 10-Q Filing — May 7, 2026
• Edgewise Therapeutics' Q3 Loss Widens Amid R&D Surge — Nov 6, 2025 Risk: high
  Edgewise Therapeutics, Inc. (EWTX) reported a net loss of $40.666 million for the three months ended September 30, 2025, an increase from a net loss of $34.129
• Edgewise Losses Widen Amid R&D Push; No Revenue Reported — Aug 7, 2025 Risk: high
  Edgewise Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company's net lo
• Edgewise Therapeutics Q1 2025: Assets $95.1M, Equity $95.2M — May 8, 2025 Risk: low
  Edgewise Therapeutics, Inc. filed its quarterly report for the period ending March 31, 2025. The company reported total assets of $95.1 million and total liabil
• Edgewise Therapeutics Q3 2024: Net Loss of $14.57M — Nov 7, 2024 Risk: high
  Edgewise Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $70.45 million and total liabilities o
• Edgewise Therapeutics Q2 2024 Update — Aug 8, 2024 Risk: medium
  Edgewise Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $93.64 million and total liabilities of $6.
• Edgewise Therapeutics Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: low
  Edgewise Therapeutics, Inc. (EWTX) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Edgewise Therapeutics, Inc. filed a 10-Q report for the period e

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX